Drug Trial Radar · NCT06933043
A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.
Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 20, 2025
Primary completion
Nov 20, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Navigator Medicines, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Southern Star Research
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess initial safety/tolerability of multiple doses of drug NAV-240. It will also learn about the profile and immunogenicity of drug NAV-240. The main question it aims to answer is: • What medical problems do participants have when taking multiple doses of drug NAV-240? Researchers will compare drug NAV-240 to a placebo (a look-alike substance that contains no drug) to see if any medical problems participants have differ between those taking drug NAV-240 and those taking placebo.
Conditions
- Healthy Volunteers
Interventions
NAV-240Drug
Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.
PlaceboDrug
Three doses of matching placebo will be administered to participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence and severity of any treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Through 6 weeks after last dose of study drug.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.